Variable Bioavailability of Oral Mercaptopurine

Fluorescence analysis of 6-mercaptopurine with the use of a nano-composite consisting of BSA-capped Au nano-clusters and core–shell Fe3O4–SiO2 nanoparticles

“…However, there are some serious side effects associated with this drug and this limits its applications. Also, the concentration of 6-MP in the plasma of the recipient varies and depends on individual differences (Zimm et al, 1983). This, therefore, affects the activity of the drug.…”

Application of HPLC to study the kinetics of a branched bi-enzyme system consisting of hypoxanthine-guanine phosphoribosyltransferase and xanthine oxidase—an important biochemical system to evaluate the efficiency of the anticancer drug 6-mercaptopurine in ALL cell line

“…So, to circumvent a relapse, higher doses of drug may be required adding to toxicity of the drug. Differences in the rate of extracellular catabolism of 6MP by XOD into 6TUA contribute to a large patient variation in the plasma 6MP concentration achieved following a uniform oral dose [9,10]. Hence, in the present context, it is very important to study the kinetic nature of this branched pathway consisting of XOD and HGPRT acting on 6MP under variable enzymatic ratios and in ALL cells.…”

Therapeutic Progress–review Xxvi Drug Therapy for the Acute Leukaemias

“…Both methotrexate and 6-mercaptopurine should be administered at doses that verge on the limit of the patient's tolerance (62). Note that bio-availability of these two drugs can vary (63,64). The addition of Cotrimoxazole to the regime (as prophylaxis against pneumocystis pneumonia) can cause greater myelosuppression but no difference to remission duration (65).…”